GlassScriptPhysician profile
Milton Wong
NPI 1942200498
$7,067.86
in general payments reported to CMS, 2019-2025
27 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,534 · 2020: $3,447 · 2021: $294 · 2022: $50.41 · 2023: $138 · 2024: $64.09 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735 · Education: $7.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.48 |
| Education | $7.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,591.37 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $299.47 | 2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $201.23 | 2019-2022 | |
| Novo Nordisk INC | $179.12 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Abbott Laboratories | $120.17 | 2020-2024 | Freestyle Libre 3 |
| Mannkind Corporation | $102.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.28 | 2019-2025 | Jardiance |
| Medtronic, INC. | $39.22 | 2023-2024 | Minimed 780g |
| Insulet Corporation | $32.18 | 2019-2023 | Omnipod |
| Sanofi-Aventis U.S. LLC | $30.71 | 2019 | |
| Ibsa Pharma INC. | $28.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $26.19 | 2019 | |
| Neurocrine Biosciences, INC. | $22.67 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.75 | 2023 | Recorlev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $20.86 | 2025 | NP Thyroid 60 |
| Amarin Pharma, INC. | $20.54 | 2019 | |
| Esperion Therapeutics, INC. | $18.79 | 2020 | |
| Corcept Therapeutics | $18.42 | 2020 | |
| Lilly USA, LLC | $15.89 | 2025 | Mounjaro, Zepbound |
| Horizon Therapeutics Plc | $15.79 | 2019 | |
| Radius Health, INC. | $15.45 | 2020 | |
| Almatica Pharma LLC | $15.22 | 2025 | Teriparatide |
| Azurity Pharmaceuticals, INC. | $14.81 | 2023 | Adthyza |
| Dexcom, INC. | $12.68 | 2021 | |
| Antares Pharma, INC. | $11.95 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.